Skip to main content
. Author manuscript; available in PMC: 2020 Aug 8.
Published in final edited form as: Nature. 2015 Jan 7;517(7535):455–459. doi: 10.1038/nature14098

Extended Data Figure 6 |. Teixobactin activity against vancomycin-resistant strains.

Extended Data Figure 6 |

a, Vancomycin intermediate S. aureus (VISA) were grown to late exponential phase and challenged with vancomycin or teixobactin. Cell numbers were determined by plating for colony counts. Data are representative of 3 independent experiments ± s.d. b, Complex formation of teixobactin with cell wall precursor variants as formed by vancomycin-resistant strains. Purified lipid intermediates with altered stem peptides were incubated with teixobactin at a molar ratio of 2:1 (TEIX:lipid II variant). Reaction mixtures were extracted with BuOH/PyrAc and binding of teixobactin to lipid II variants is indicated by its absence on the thin-layer chromatogram. Migration behaviour of unmodified lipid II is used for comparison. The figure is representative of 3 independent experiments.

HHS Vulnerability Disclosure